Kazazian Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Kazazian Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,450	Closed	-$84K	–	49
2025 Q1	$84K	Buy	+10,450	New	+$84.7K	0.07%	55
2019 Q3	$446K	Hold	83,572	–	–	0.6%	35
2019 Q2	$550K	Sell	83,572 -13,484	-14%	-$85.9K	0.65%	33
2019 Q1	$631K	Sell	97,056 -20,000	-17%	-$133K	0.88%	28
2018 Q4	$798K	Sell	117,056 -53,300	-31%	-$307K	1.08%	25
2018 Q3	$1.13M	Hold	170,356	–	–	1.06%	24
2018 Q2	$959K	Buy	170,356 +14,230	+9%	+$79.4K	0.88%	28
2018 Q1	$810K	Hold	156,126	–	–	0.85%	30
2017 Q4	$707K	Buy	156,126 +16,189	+12%	+$89.9K	0.72%	33
2017 Q3	$877K	Buy	139,937 +73,633	+111%	+$464K	1.07%	22
2017 Q2	$406K	Buy	66,304 +21,304	+47%	+$144K	0.61%	32
2017 Q1	$330K	Buy	+45,000	New	+$208K	0.46%	29

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kazazian Asset Management's AUPH Position: Q2 2025 in Review

Kazazian Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 10,450 shares — an estimated $84K sold.

Kazazian Asset Management first reported a position in AUPH in Q1 2017 and held it in 12 quarters. The position peaked at $1.13M in Q3 2018. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

Kazazian Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Kazazian Asset Management sold 10,450 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $84K.
Kazazian Asset Management first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 12 quarters.
Kazazian Asset Management's Aurinia Pharmaceuticals position peaked at $1.13M in Q3 2018.
219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Kazazian Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.